MedTrace Logo

Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)

NCT00372723 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-04-26

No results posted yet for this study

Summary

To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters.

Conditions

  • Toxic Epidermal Necrolysis

Interventions

DRUG

Remicaide (infliximab)

a single dose infusion of 5mg/kg Remicade (Infliximab)

Sponsors & Collaborators

  • Loyola University

    lead OTHER

Principal Investigators

  • Richard Gamelli, MD · Loyola University Medical Center, Department of Surgery

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2011-06-30
Completion
2011-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00372723 on ClinicalTrials.gov